At Amunix, we have developed a novel half-life extension technology based on XTEN, a hydrophilic, unstructured polypeptide which can be recombinantly fused or chemically conjugated to other peptides, proteins, and small molecules. We have applied our XTEN technology platform to targets in a wide range of therapeutic areas, creating new protein pharmaceuticals characterized by improved efficacy, safety, and dosing.

Amunix Announces Licensing Agreement for Its Proprietary XTEN Technology

Mountain View, CA – [January 21, 2013] – Amunix, Inc., today announced that it has entered into a worldwide research collaboration and licensing agreement with Janssen Biotech, Inc. and its affiliates (“Janssen”).Amunix will combine its XTEN half-life extension technology with protein and/or peptide therapeutics selected by Janssen.

GLP2-2G-XTEN preclinical data published in PLOS ONE

Amunix has published preclinical characterization of a novel recombinant protein, GLP2-2G-XTEN. Pharmacokinetic analysis of the molecule suggests that it may offer superior therapeutic benefit for treatment of gastrointestinal diseases when compared to current therapeutic regimens.